Surmodics expects to beast Q3 consensus:
This article was originally published in Clinica
Coating technology company Surmodics expects third-quarter revenues of $7.4-7.7m - ahead of consensus expectations of $7m. The Eden Prairie, Minnesota company is expecting EPS of $0.10-0.11, compared with analysts' estimates of $0.10. The company generates a significant portion of its royalties from sales of its patented photoactivated coating processes to medical device manufacturers around the world. The company expects a third-quarter revenue increase of at least 33%.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.